Travere Therapeutics (TVTX) Long-Term Investments (2014 - 2019)
Travere Therapeutics (TVTX) posted Long-Term Investments of $15.0 million for Q2 2019, little changed on a QoQ basis from $15.0 million in Q1 2019, and little changed year-over-year from $15.0 million in Q2 2018.
Travere Therapeutics (TVTX) Long-Term Investments (2014 - 2019) Analysis & Trends
Travere Therapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $15.0 million for Q2 2019.
- Quarterly Long-Term Investments changed 0.0% year-over-year to $15.0 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $15.0 million (changed 0.0% YoY) and the FY2018 annual result came in at $15.0 million, changed N/A from the prior year.
- Long-Term Investments was $15.0 million for Q2 2019 at Travere Therapeutics, roughly flat from $15.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $15.0 million in Q1 2018 and bottomed at $15.0 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 15.00 Mn |
| Mar 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 15.00 Mn |
| Sep 30, 2018 | 15.00 Mn |
| Jun 30, 2018 | 15.00 Mn |
| Mar 31, 2018 | 15.00 Mn |
| Sep 30, 2014 | 400,000.00 |